VYNE Therapeutics (VYNE) Change in Accured Expenses (2017 - 2026)

VYNE Therapeutics' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 53.41% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.9 million (down 290.08% YoY) and the FY2025 annual result came in at -$12.3 million, down 304.74% from the prior year.
• Change in Accured Expenses was -$1.2 million for Q1 2026 at VYNE Therapeutics, up from -$6.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.5 million in Q2 2024 and bottomed at -$9.6 million in Q1 2022.
• A 5-year average of -$885600.0 and a median of -$512000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 4782.93% — and 2024, when it surged 1072.73%.
• VYNE Therapeutics' Change in Accured Expenses stood at $2.5 million in 2022, then plunged by 60.61% to $993000.0 in 2023, then surged by 121.55% to $2.2 million in 2024, then slumped by 391.18% to -$6.4 million in 2025, then soared by 81.89% to -$1.2 million in 2026.
• Business Quant data shows VYNE's Change in Accured Expenses at -$1.2 million in Q1 2026, -$6.4 million in Q2 2025, and -$2.5 million in Q1 2025.